Myriad Genetics (MYGN) CPO has shares withheld to cover taxes

Rhea-AI Filing Summary

Myriad Genetics Chief People Officer Shereen Solaiman reported a tax-related share withholding connected to vesting restricted stock units. On March 1, 2026, 1,675 shares of common stock were withheld at a price of $4.61 per share to cover tax obligations. After this tax-withholding disposition, Solaiman directly held 109,288 shares of Myriad Genetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Solaiman Shereen

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		F		1,675(1)	D	$4.61	109,288	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on February 27, 2026.

Remarks:

	By: Justin Hunter For: Shereen Solaiman	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Myriad Genetics (MYGN) report for Shereen Solaiman?

Myriad Genetics reported that Chief People Officer Shereen Solaiman had 1,675 common shares withheld to cover taxes on vesting restricted stock units. The shares were valued at $4.61 each, reflecting the closing price used to calculate the tax obligation.

Was the Myriad Genetics (MYGN) Form 4 transaction an open-market sale?

The Form 4 transaction was not an open-market sale. Shares were withheld by Myriad Genetics to satisfy tax withholding obligations from vesting restricted stock units, effectively a non-cash disposition rather than a voluntary sale into the market.

How many Myriad Genetics (MYGN) shares does Shereen Solaiman hold after this transaction?

Following the tax-withholding disposition, Shereen Solaiman directly holds 109,288 shares of Myriad Genetics common stock. This figure reflects her reported ownership after 1,675 shares were withheld to cover taxes on previously granted restricted stock units.

What price was used to determine the Myriad Genetics (MYGN) tax-withholding shares?

The number of shares withheld was based on the closing price of Myriad Genetics common stock on February 27, 2026. That price was $4.61 per share, which determined how many shares were needed to satisfy the tax liability.

What does transaction code "F" mean in the Myriad Genetics (MYGN) Form 4?

Transaction code "F" indicates payment of an exercise price or tax liability by delivering securities. In this case, it reflects Myriad Genetics withholding 1,675 shares from Shereen Solaiman’s restricted stock unit vesting to cover associated tax withholding obligations.